Halia Therapeutics, Inc.
Lehi, UT · Founded 2017 · CIK 0001829255 · Biotech · Private
NLRP3-targeted genetic therapies for inflammation-related chronic diseases
haliatx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $27M
- 5 Form D · Aug 2026
- 1 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 7 granted · 33 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20202021202220232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,344,990 | |
| Private capital raised | Form D · SEC | $4,999,994 | |
| Private capital raised | Form D · SEC | $12,223,338 | |
| Private capital raised | Form D · SEC | $336,833 | |
| Private capital raised | Form D · SEC | $3,486,474 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1729 | Chicago Biosolutions, Inc. | — | — |
| 1730 | DEMERX, INC. | — | $290K |
| 1731 | Design Therapeutics, Inc. | — | $171M |
| 1732 | Halia Therapeutics, Inc. | — | $27M |
| 1733 | Iterum Therapeutics plc | — | $127M |
| 1734 | Jnana Therapeutics | — | $110M |
| 1735 | STRYKAGEN CORPORATION | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David BearssDirector · Executive Officer · Promoter
- Jared BearssDirector · Executive Officer · Promoter
- Jeffrey BurtonExecutive Officer
- John KauweDirector · Promoter
- Mike McCullarDirector · Executive Officer
- MIKE MCCULLARDirector · Executive Officer
- Todd PedersenDirector
- Gary SabinDirector
- Jim SavasDirector
- JIM SAVASDirector
Patents
- NEK7 Inhibitorsgranted
- Inhibitors Of LRRK2 Kinaseapplication
- Inhibitors Of LRRK2 Kinasegranted
- NEK7 Inhibitorsapplication
- PYRROLE[2,3-B]PYRIDINE Derivatives As TYRO3 Inhibitorsapplication
- TYRO3 Inhibitorsapplication
- NEK7 Inhibitorsapplication
- NEK7 Inhibitorsapplication
- NEK7 Inhibitorsapplication
- Inhibitors Of NEK7 Kinasegranted
- NEK7 Inhibitorsapplication
- Inhibitors Of LRRK2 Kinasegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.